From Gene to Cure

GCure aims at unlocking the Research & Innovation (R&I) potential of the University of Coimbra (UC) in Biomolecular Medicine.

The actions involves establishing an ERA Chair dedicated to next-generation Gene Therapy Vectors, building upon UC's strong foundation in Gene Therapy research at the Center for Neuroscience and Cell Biology (CNC-UC).

Gene Therapy, utilizing genetic material to treat or prevent diseases at their root cause, promises a significant shift in medical treatment paradigms, particularly for inherited diseases.

With 24 approved gene therapies and ongoing developments, the field shows promise, yet faces challenges, notably in viral vector-based delivery systems.The specific objectives of GCure include creating a core R&I cluster on next-generation Gene Therapy Vectors, optimizing UC's viral vector production facility, establishing a training program on Gene Therapy knowledge & technology transfer, expanding UC's participation in collaborative R&I projects, and enhancing UC's international recognition in the field.

To achieve these goals, renowned gene therapy pioneer R. Jude Samulski has been appointed as the GCure ERA Chair holder.

Samulski's expertise and achievements in the field, including multiple FDA-approved gene therapies and numerous patents, ensure leadership in advancing UC's Gene Therapy initiatives.GCure also aims to attract international researchers to UC, fostering a sustainable research group and enhancing resources.

Synergies between diverse research subjects will improve UC's research and innovation performance, attracting high-value collaborations and funding opportunities.

In-house reforms in research management and open science strategies, coupled with a robust training program, will maximize GCure's contribution to the knowledge-based economy and society.

GCure represents a strategic endeavor to propel UC to the forefront of Gene Therapy research and innovation, fostering significant advancements in healthcare and well-being.